Type 2 Diabetes

Professor John McMurray explains why he is not as displeased as some colleagues are with the uptake of SGLT2 inhibitor prescribing rates for patients with heart failure or chronic kidney disease.

Retinal nerve fiber layer density also appears to be influenced by presentation of both conditions.

Geeta Lalchandani-Lalwani, MD discusses the importance of early DR detection as well as findings from her study that suggest a need for more personalized therapies.

For patients with ETDRS DRSS scores of 47-53, about 40% experienced 2-step DR worsening by year 5.

In honor of World Diabetes Day, we reached out to Lucia Novak, CRNP, to get her perspective on the role of nurses in the diabetes care model as "The Nurse and Diabetes" has been chosen as the official theme of this year's World Diabetes Day.

In data presented at AAO 2020, researchers discover new methods for detecting different underlying conditions.

A practicing endocrinologist offers her thoughts on a recent change by the AACE from the American Association of Clinical Endocrinologists to the American Association of Clinical Endocrinology.

Analysis of data from the 5000-patient Look AHEAD Trial details the varying effects of changes in lean mass, fat mass, and waist circumference, respectively, on risk of heart failure and myocardial infarctions in patients with type 2 diabetes.

A new health care pathway could be safe to implement in clinical practice.

A nephrologist and professor from the University of Toronto offers insight into the results of a key kidney outcomes analysis of the VERTIS-CV trial.

Analysis of data from the SUSTAIN program suggests adverse gastrointestinal events contributed little to superior weight loss seen with semaglutide versus other GLP-1 receptor agonists.

Dr. Melissa Young details the evolution of technology in diabetes management from the perspective of a practicing endocrinologist.

A recent trial found incorporating an online weight loss program to population health management strategies was linked to greater reductions in body weight.

The Norfolk Diabetes Prevention Study is the largest type 2 diabetes prevention trial since the US Diabetes Prevention Program more than 20 years ago.

Analysis of data from the SUSTAIN program suggests adverse gastrointestinal events contributed little to superior weight loss seen with semaglutide versus other GLP-1 receptor agonists.

An extension study of the phase 3 trial indicate combination therapy with exenatide and dapagliflozin was effective 104 weeks after randomization in patients with type 2 diabetes and inadequate glycemic control despite metformin therapy.

An analysis of data from 3 major studies details associations between diets characterized by intake of pro versus anti-inflammatory foods with incidence of cardiovascular disease.